Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: Aug 11, 2025
Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development
Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases
Read more at globenewswire.com
